Thoratec’s Hammering (THOR)
Thoratec Corporation (NASDAQ: THOR) is having a rough morning. The heart failure device company has a product recall it announced last Friday, and medical device recalls are not what the public likes to hear…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 348Boston Scientific Co-Founders Hit By Margin Calls (BSX)
Today after the close, SEC Filings have shown that Boston Scientific Corp. (NYSE: BSX) co-founders have been forced to sell more common stock to meet margin calls. Unfortunately this isn’t the first pony ride…
Amgen Becomes A Biotech Safety Stock (AMGN)
Amgen Inc. (NASDAQ: AMGN) has just posted earnings. The biotech giant for anemia treatments posted $1.09 GAAP EPS and adjusted earnings of $1.23 non-GAAP EPS and $3.875 billion in revenues. First Call had estimates…
Biotech Implosion: Dynavax (DVAX)
Dynavax Technologies Corp. (NASDAQ: DVAX) is the latest biotech implosion as shares are down some 75% today. The company gave an update on an FDA clinical hold on its investigational vaccine HEPLISAV with partner…
Pfizer (PFE) Does Some Good, Viagra Rocks On
Once all of the one-time charges were washed out of the numbers, Pfizer recorded adjusted income of $4.2 billion, an increase of 5% compared with $4.0 billion in the year-ago quarter, and EPS of $.62,…
Day Trader Alert: Syneron medical (ELOS)
Syneron Medical Ltd. (ELOS) is generally a thin volume stock, although it may see more active trading as the opening bell gets closer. Shares are indicated lower on an earnings warning. It sees $0.11…
Gilead Boosted Partly By Currencies (GILD)
Gilead Sciences Inc. (NASDAQ: GILD) has just issued its third quarter earnings at $0.52 net EPS and $0.55 non-GAAP EPS and $1.37 billion in revenue. First Call had estimates at $0.49 non-GAAP EPS and…
Genentech Mixes Top-Line & Bottom-Line Numbers (DNA)
Genentech, Inc. (NYSE: DNA) today posted earnings of $0.81 per share and $3.408 billion in revenue. That’s below First Call estimates of $0.88 on $3.36 billion in revenue. For what this is worth, Genentech…
Looking Beyond Genentech Earnings (DNA)
After today’s close, we are expecting the earnings report of of biotech giant Genentech, Inc. (NYSE: DNA). First Call estimates are for $0.88 EPS on $3.36 billion in revenue. Today is going to be…
J&J Earnings: Size Does Matter (JNJ)
Johnson & Johnson (NYSE: JNJ) is showing that some companies can get it right despite tough times. The company has beat earnings and is even raising its fiscal 2008 guidance. The consumer products and…
Merck (MRK): More Trouble With Vioxx
A lot of people believe that Merck (MRK) knew a lot more about the dangers of its arthritis drug Vioxx than the company ever let on. Heart problems were apparently a by-product of using…
Can deCODE Genetics Escape Icelandic Woes? (DCGN)
If you think things are bad here in the U.S., Iceland is experiencing something far worse. The country is on the verge of teetering, it is nationalizing its banks, and it is on the…
Dendreon’s Move Still Leaves Many Questions (DNDN)
Dendreon Corp. (NASDAQ: DNDN) was an incredible performer today, and one which makes you wonder how well it would have done had the stock market not been so ugly. Its interim data from Phase…
Icahn Wins Blue Ribbon in ImClone Race (IMCL, LLY, BMY, MRK)
Carl Icahn appears to have won a blue ribbon for ImClone Systems (NASDAQ: IMCL) shareholders. The biotech stock is trading up on a very weak trading day after what many had deemed as a…
OSI Phase III Falls Short (OSIP, DNA)
OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is getting hit hard in early trading this morning. The biotech has released data showing that a Phase III trial of Genentech’s (NYSE: DNA) Avastin combined with Tarceva in…